Loading…
← CockpitCompetitor Analysis › SOPH Sophia Genetics SAOpen in the cockpit ↗

Sophia Genetics SASOPHCompetitor analysis, valuation and peers

United States · USD·Information Technology›Packaged Software
Momentum leader 85
Mkt cap
$636M
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$4.85M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-170.4 pp
WACC 10.1%
Hurdle
n/a
no reverse DCF
Next earnings
111 days
9 Mar 2027
Close · USD$7.47
1D+0.3%
1W+0.1%
1M+7.8%
3M-10.3%
6M+53.4%
YTD+60.0%
1Y+84.4%
ATR %7.5%
Beta1.52
52w lowhigh16.8% off high

What Sophia Genetics does

Employees: 415

Sophia Genetics at a glance

Size Sophia Genetics (SOPH) is a United States Information Technology company (Packaged Software) with a market value of $636M, the 2518th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.47 on 18 Nov 2026.

Performance Over six months the shares gained 53.4%, against -23.4% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 24.1% over the last twelve months (peer median +9.4%); the operating margin is -79.9% (peer median -0.8%).

Valuation It trades at 6.6× enterprise value to sales against a peer median of 1.7× (3rd most expensive of 21).

Capital Return on invested capital runs 170.4 points below its cost of capital (10.1% WACC).

Short interest Short interest is 1.4% of the free float (30 Oct 2026).

Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026SOPH 148Peer median 77
Six months, rebased to 100: Sophia Genetics against the median of its 20 peers (local-currency closes).

Sophia Genetics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$91.0M$77.3M$65.2M$62.4M$47.6M
Revenue growth—+19%+4%+31%—
Gross profit$60.4M$47.8M$38.9M$36.7M$26.8M
EBITDA-$61.7M-$61.4M-$58.9M-$68.6M-$83.9M
Net income-$81.1M-$79.0M-$62.5M-$79.0M-$87.4M
Free cash flow-$45.1M-$38.6M-$43.1M-$50.1M-$74.2M
Capital expenditure$10.2M$8.62M$8.18M$9.23M$10.4M
Total debt$61.0M$63.0M$30.0M$18.6M$16.7M

Quarterly statements and history in the cockpit →

Sophia Genetics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%-10%0%+10%66876036363002272643TXT3014913477000068NEWGEN6007563693ENGH688109300533600571PRTHALFASPTSOPH6-month return →1-month return →
Up and to the right = strong over both horizons. Sophia Genetics is the large dot.

Fundamentals: revenue growth against valuation

0%+50%0×5×10×66876036363002272643TXT3477000068NEWGEN6007563693ENGH688109300533600571UBIPRTHSPTSOPHRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sophia Genetics is the large dot.

Sophia Genetics competitors and peer comparison

How Sophia Genetics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sophia Genetics against its 20 peers (data as of 18 Nov 2026)
MeasureSOPHPeer medianRank in peer set
1-month return+7.8%-9.2%2nd highest of 21
6-month return+53.4%-23.4%2nd highest of 21
Distance from 52-week high-16.8%-50.3%3rd highest of 21
Revenue growth (TTM)+24.1%+9.4%6th highest of 21
Operating margin-79.9%-0.8%3rd lowest of 21
EV / Sales6.6×1.7×3rd most expensive of 21
ROIC minus cost of capital-170.4 pp-10.1 pplowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sophia Genetics SOPHUnited States$636M+53%+24%-80%6.6×n/an/a
JST 6687.HKHong Kong$637M-22%+26%11%1.2×-8.3%+30.3%
Linewell Software 603636.SSChina$638M-27%-42%-111%9.7×14.0%-11.5%
Shenzhen Sunshine Laser & Electronics Technology 300227.SZChina$639M-37%+88%-14%2.2×47.5%+12.7%
CaoCao 2643.HKHong Kong$633M-63%+38%-3%0.5×n/an/a
TXT e-solutions TXT.MIItaly$632M+38%+22%6%1.6×11.5%+41.8%
Hansong (Nanjing) Technology 301491.SZChina$632M-35%+26%10%1.3×-2.7%+9.7%
Sphere 347700.KSSouth Korea$640M-62%+261%5%5.0×n/an/a
Manycore Tech 0068.HKHong Kong$631M-84%+9%0%3.5×n/an/a
Newgen Software Technologies NEWGEN.NSIndia$630M-10%+6%24%2.9×20.2%+18.5%
Inspur Software 600756.SSChina$629M-25%-25%-25%3.2×n/an/a
AIC 3693.TWOTaiwan$643M-2%+19%11%2.2×9.2%+20.2%
Enghouse Systems ENGH.TOCanada$644M+1%-5%19%1.4×-15.3%-0.2%
Pinming Technology 688109.SSChina$627M-41%-13%-6%9.7×39.1%+2.9%
Shenzhen Bingchuan Network 300533.SZChina$649M-28%-5%-10%1.0×0.6%+46.0%
Sunyard Technology 600571.SSChina$623M-29%+1%-1%1.9×57.6%+10.2%
UBISOFT Entertainment UBI.PAFrance$649M-20%-27%-87%0.7×n/an/a
Priority Technology PRTHUnited States$653M+36%+10%13%1.5×3.3%+18.7%
Alfa Financial Software ALFA.LUnited Kingdom$653M+7%+8%30%3.7×-1.5%+9.9%
Sprout Social SPTUnited States$615M+56%+11%-2%1.1×-0.4%+28.0%
Beijing Thunisoft 300271.SZChina$611M-17%+11%-9%1.6×n/an/a

Questions

Which companies are Sophia Genetics's closest peers?
The cockpit's peer set: JST (6687.HK), Linewell Software (603636.SS), Shenzhen Sunshine Laser & Electronics Technology (300227.SZ), CaoCao (2643.HK), TXT e-solutions (TXT.MI), Hansong (Nanjing) Technology (301491.SZ), Sphere (347700.KS), Manycore Tech (0068.HK).
Is Sophia Genetics expensive compared with its peers?
On ev / sales it trades at 6.6× against a peer median of 1.7×, 3rd most expensive of 21 in its peer set.
How has Sophia Genetics stock performed?
Over six months to 18 Nov 2026 the shares returned +53.4% against -23.4% for the median peer; over one year +84.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.